Living with myasthenia gravis (MG)? Clinical trial seeking participants for new study

Living with myasthenia gravis (MG)? Clinical trial seeking participants for new study

(BPT) – The human body is made up of voluntary and involuntary muscles. Involuntary muscles are those that cannot be controlled at will, like the beating of a heart. Voluntary muscles are those that you can consciously control – the opening and closing of your hand for example. Most of us take the use of our voluntary muscles for granted and don’t deliberately think when our brain signals them to work. However, for people living with myasthenia gravis (MG), their brain tries signaling the voluntary muscles to contract but they don’t respond normally.

MG is a chronic autoimmune condition that can cause muscle weakness. Normally, the body makes antibodies to attack viruses or bacteria that enter the body, but in people with MG, antibodies attack receptors that allow your brain and nerves to communicate with your muscles and tell them to move. These antibody attacks cause muscle weakness most commonly in the eye muscles, muscles that control chewing and swallowing, arm and leg muscles, and muscles that control breathing.

Treatment for MG

MG affects everyone differently and there is currently no cure for the disease; however, there are treatments available or in development that can help relieve the symptoms of MG.

In fact, researchers are looking for more people to participate in a trial to assess the safety and benefits of inebilizumab for the treatment of MG. Inebilizumab is an already FDA-approved treatment for people living with another chronic autoimmune condition called neuromyelitis optica spectrum disorder (NMOSD). Clinical trials, also known as research studies, help researchers determine how safe and effective treatments are for certain diseases.

If you live with MG, ask your doctor about enrolling in a clinical trial. To learn more about the study, and to see if you may qualify to participate, please visit


No Responses

Write a response